Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Publications show all

Resolvyx Pharmaceuticals has published 2 articles.

Patents show all

40Applications8Issued

Clinical Trials show all

1Phase 11Phase 2

SEC Filings show all

D3

SEC Form D Funding Events

DateOfferedSoldType
2010-11-08$2,500,000$2,500,000Debt, Option to Acquire, Security to be Acquired
2010-06-18$1,200,000$1,200,000Debt, Option to Acquire, Security to be Acquired
2008-08-06UnknownUnknownOther (Paper Filing)

Key Executives

  • Philip J. Vickers
    Executive Officer, Director
  • James Nichols
    Executive Officer
  • Per Gjorstrup
    Executive Officer
  • C. Eric Schwartz
    Executive Officer
  • Timothy J. Barberich
    Director
  • Douglas Cole
    Director
  • Jean-francois Formela
    Director
  • Keith Manchester
    Director
  • George M. Milne, Jr.
    Director
  • Gregory Weinhoff
    Director